Earnings Brief

AbbVie Q2 Revenue Tops $17.0B on Immunology Strength, but Trims Profit Outlook on Apogee Deal

AbbVie posted Q2 2026 revenue of $17.0 billion, up 10.2% year-over-year. Adjusted EPS came in at $3.65, and the company trimmed its full-year profit outlook following the Apogee Therapeutics acquisition.

Justin Jeon·July 31, 2026 at 23:15·4 min

abbvie-q2-revenue-beats-apogee-acquisition-profit-outlook

AIKey Summary

AbbVie's Q2 2026 revenue rose 10.2% YoY to $17.0 billion, beating expectations
The company also cut its full-year profit outlook due to the Apogee Therapeutics acquisition

AbbVie reported second-quarter 2026 revenue of $17.0 billion, up 10.2% year-over-year and above market expectations, according to an SEC Form 8-K filing. Shares of AbbVie fell 2.22% to $257.45 on the day.

📊 Price at Time of Writing (July 31, 2026, 23:11 KST)
$257.45 ▼ -2.22%

Q2 Results at a Glance

AbbVie's second-quarter revenue was driven by its immunology business. Sales of Skyrizi and Rinvoq surged, while sales of the older drug Humira declined sharply. Adjusted operating margin (excluding interest, taxes, and depreciation/amortization) came in at 48.3%.

Revenue: $17.0 billion, +10.2% year-over-year
Earnings per share (EPS): $2.03 GAAP (+290.4% YoY), $3.65 adjusted (+22.9% YoY)
Operating margin (as a % of revenue): 37.9% GAAP, 48.3% adjusted (excluding interest, taxes, and depreciation/amortization)

Guidance Update

AbbVie lowered its full-year 2026 adjusted EPS guidance to a range of $13.87 to $14.07, down from $13.91 to $14.11 previously. The revision reflects a $0.14-per-share dilutive impact from the pending acquisition of Apogee Therapeutics, expected to close in the third quarter. It also includes a $0.58-per-share charge tied to acquisition-related research and development expenses (IPR&D and milestone payments). AbbVie Chairman and CEO Robert Michael said the Apogee deal will strengthen the company's immunology franchise and enhance shareholder value, adding that AbbVie's long-term outlook remains very strong.

Market Reaction

Reuters and other outlets noted that AbbVie's second-quarter revenue beat market expectations. Barron's and Yahoo Finance, however, reported that the lowered profit outlook tied to the Apogee acquisition and other earnings metrics fell short of market expectations. Following the results, AbbVie shares fell 2.22% to $257.45. The specific purchase price for the Apogee Therapeutics acquisition was not disclosed in the filing.

Segment Breakdown

Immunology: $8.786 billion, +15.1% year-over-year
Neuroscience: $3.228 billion, +20.3% year-over-year
Oncology: $1.650 billion, -1.5% year-over-year
Aesthetics: $1.282 billion, +0.3% year-over-year

This article was automatically generated based on the original SEC Form 8-K filing and media reports, with the aim of delivering key data promptly after the announcement. Readers are encouraged to review the company's official filing before making trading decisions. Prices reflect the time of writing and may differ from current levels.

Related Assets

Gurus Holding This Stock

JPMorgan ChaseABBV 0.8%

National Pension ServiceABBV 0.7%

Ken FisherABBV 0.7%

State StreetABBV 0.6%

Norges BankABBV 0.6%

VanguardABBV 0.6%

BlackRockABBV 0.6%

Goldman SachsABBV 0.4%

T. Rowe PriceABBV 0.3%

MORE — EARNINGS BRIEF

ExxonMobil Q2 2026 Net Income Hits $14.5B, Triples QoQ — But EPS Misses Estimates

ExxonMobil posted second-quarter 2026 net income of $14.5 billion and earnings per share of $3.48. That's more than triple the prior quarter, though media outlets said results still fell slightly short of Wall Street estimates. Shareholder returns totaled $9.4 billion.

XOM

Jul 31, 23:09

Colgate Q2 Revenue Rises 4.9% to $5.36B, Stock Falls 2% Despite EPS Beat

Colgate's Q2 revenue rose 4.9% year-over-year to $5.361 billion. Adjusted EPS came in at 99 cents, beating estimates by 4 cents, but GAAP EPS fell 5% to 86 cents, and shares dropped over 2%.

Jul 31, 21:11

Linde Q2 Revenue Rises 9% YoY to $9.3B, Adjusted EPS Beats Estimates

Linde posted Q2 2026 revenue of $9.3 billion and adjusted EPS of $4.50, up 9% and 10% year-over-year respectively, beating market expectations. The company also raised its full-year guidance.

LIN

Jul 31, 21:06

Rivian Q2 Revenue Rises 27% to $1.658 Billion as R2 Deliveries Begin

Rivian's second-quarter revenue rose 27% year-over-year to $1.658 billion. Gross profit turned positive at $179 million, and the operating loss narrowed. The company also began external deliveries of its lower-priced R2 SUV during the quarter.

RIVN

Jul 31, 09:08

Nvidia's 85% Revenue Surge Still Couldn't Lift the Stock — A Textbook 'Sell the News' Event

Nvidia posted $81.6B in Q1 revenue (+85% YoY) and guided Q2 to $91B — demolishing every estimate. Yet the stock fell. A textbook buy-the-rumor, sell-the-news moment driven by 30x forward earnings valuation.

Nokia Surges 140% YTD — Nvidia's $1B Bet Rebrands It as an AI Infrastructure Play

Nokia started as a paper mill in 1865. In 2026, it's one of the market's hottest AI infrastructure stocks — up 140% YTD after Nvidia's $1B strategic investment and a surge in AI data center optical network orders.

eBay's 176% Three-Year Rally Decoded — Is the Buyback Engine Built to Last?

eBay stock surged 176% over three years on a dual engine of earnings growth and buybacks. But with 40% of shareholder returns funded by debt and TikTok Shop looming, the machine faces real stress tests.